Bluebird Bio Shares Are Trading Lower After the FDA Announced an Investigation Into a Serious Risk of Hematologic Malignancy Following Skysona.
Bluebird Bio Shares Are Trading Lower After the FDA Announced an Investigation Into a Serious Risk of Hematologic Malignancy Following Skysona.
bluebird bio的股票在FDA宣佈對Skysona後續出現血液惡性腫瘤的嚴重風險進行調查後，交易價格下跌。
Bluebird Bio Shares Are Trading Lower After the FDA Announced an Investigation Into a Serious Risk of Hematologic Malignancy Following Skysona.
bluebird bio的股票在FDA宣佈對Skysona後續出現血液惡性腫瘤的嚴重風險進行調查後，交易價格下跌。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間